Cardiac Pharmacology: Difference between revisions

Jump to navigation Jump to search
no edit summary
No edit summary
No edit summary
Line 368: Line 368:
|Heart Failure
|Heart Failure
|Captopril: 12.5mg 3 times daily
|Captopril: 12.5mg 3 times daily
|ESC Guidelines (European Heart Journal (2012) 33, 2569–2619 doi:10.1093/eurheartj/ehs215):  
|ESC Guidelines (European Heart Journal (2012) 33, 2569–2619
doi:10.1093/eurheartj/ehs215):  
Post STEMI: Class IA
Post STEMI: Class IA


ESC and EASD Guidelines (European Heart Journal doi: 10.1093/eurheart/ehl261)  
ESC and EASD Guidelines (European Heart Journal doi: 10.1093/eurheart/ehl261)
Diabetic patients: Class IC
Diabetic patients: Class IC


Line 399: Line 400:
|
|
|Angiotensin Receptor Blockers
|Angiotensin Receptor Blockers
|Losartan. Candesartan
|Losartan. Candesartan
|Hypertension
|Hypertension
|Losartan: 50mg once daily
|Losartan: 50mg once daily
Line 506: Line 507:
AF (Poorly tolerated): Class IIaC
AF (Poorly tolerated): Class IIaC
AF (Stable flutter): Class IC
AF (Stable flutter): Class IC
Prophylaxis of SVT during pregnancy: Class IIaB
Prophylaxis of SVT during pregnancy: Class IIaB
|
|
|-
|-
|
|
Line 743: Line 744:
|-
|-
|Lipid-Lowering Drugs |Statins
|Lipid-Lowering Drugs |Statins
|Simvastatin, Atorvastatin Primary hyper-cholesterolaemia, combined hyperlipidaemia Simvastatin: 10-20mg once daily ESC and EASD Guidelines (European Heart Journal doi: 10.1093/eurheart/ehl261)
|Simvastatin, Atorvastatin |Primary hyper-cholesterolaemia, combined hyperlipidaemia |Simvastatin: 10-20mg once daily |ESC and EASD Guidelines (European Heart Journal doi: 10.1093/eurheart/ehl261)
Dyslipidaemia: Class IA
Dyslipidaemia: Class IA
Low HDL-C: Class IIbB
Low HDL-C: Class IIbB
Line 757: Line 758:
doi:10.1093/eurheartj/ehs092):
doi:10.1093/eurheartj/ehs092):
Hypertension in diabetics: Class IA
Hypertension in diabetics: Class IA
ACS: Class IA Oedema (2.7%), abdominal pain (5.9%), nausea (5.4%), atrial fibrillation (5.7%), constipation (2.2%), gastritis (4.9%), diabetes mellitus (4.2%), myalgia (3.7%), headache (2.5%), insomnia (4.0%), vertigo (4.5%), bronchitis (6.6%), sinusitis (2.3%), eczema (4.5%), urinary tract infection (3.2%)
ACS: Class IA
Familial hyper-cholesterolaemia Simvastatin: 40mg once daily ESC and EASD Guidelines (European Heart Journal doi: 10.1093/eurheart/ehl261)
|Oedema (2.7%), abdominal pain (5.9%), nausea (5.4%), atrial fibrillation (5.7%), constipation (2.2%), gastritis (4.9%), diabetes mellitus (4.2%), myalgia (3.7%), headache (2.5%), insomnia (4.0%), vertigo (4.5%), bronchitis (6.6%), sinusitis (2.3%), eczema (4.5%), urinary tract infection (3.2%)
HeFH: Class IC
|-
Prevention of cardiovascular events 20-40mg once daily ESC and EASD Guidelines (European Heart Journal doi: 10.1093/eurheart/ehl261):
|
Class IA
|
Fibrates Gemfibrozil Hyperlipidaemias of types IIa, IIb, III, IV and V Gemfibrozil: 0.9-1.2mg daily ESC and EAS Guidelines (European Heart Journal (2011) 32, 1769–1818
|
|Familial hyper-cholesterolaemia |Simvastatin: 40mg once daily |ESC and EASD Guidelines (European Heart Journal doi: 10.1093/eurheart/ehl261)
HeFH: Class IC
|
|-
|
|
|
|Prevention of cardiovascular events
|20-40mg once daily
|ESC and EASD Guidelines (European Heart Journal doi: 10.1093/eurheart/ehl261):
Class IA
|
|-
|
|Fibrates
|Gemfibrozil |Hyperlipidaemias of types IIa, IIb, III, IV and V
|Gemfibrozil: 0.9-1.2mg daily
|ESC and EAS Guidelines (European Heart Journal (2011) 32, 1769–1818
doi:10.1093/eurheartj/ehr158)
doi:10.1093/eurheartj/ehr158)
Low HDL-C: Class IIbB
Low HDL-C: Class IIbB
Transplant patients (with HTG, low HDL-C): Class IIbC gastro-intestinal disturbances including dyspepsia (19.6%), nausea (4%), abdominal pain (9.8%), diarrhoea (7.2%), vomiting (1.2%); headache (1.2%), fatigue (3.8%), vertigo (1.5%), eczema, rash (1.7%), atrial fibrillation (0.7%), pancreatitis, appendicitis, disturbances in liver function including hepatitis and cholestatic jaundice, dizziness, paraesthesia, sexual dysfunction, thrombocytopenia, anaemia, leucopenia, eosinophilia, bone-marrow suppression, myalgia, myopathy, myasthenia, myositis accompanied by increase in creatine kinase, blurred vision, exfoliative dermatitis, alopecia, and photosensitivity
Transplant patients (with HTG, low HDL-C): Class IIbC
- Ezetimibe Primary and familial hyper-cholesterolaemia 10mg once daily ESC and EAS Guidelines (European Heart Journal (2011) 32, 1769–1818
|Gastro-intestinal disturbances including dyspepsia (19.6%), nausea (4%), abdominal pain (9.8%), diarrhoea (7.2%), vomiting (1.2%); headache (1.2%), fatigue (3.8%), vertigo (1.5%), eczema, rash (1.7%), atrial fibrillation (0.7%), pancreatitis, appendicitis, disturbances in liver function including hepatitis and cholestatic jaundice, dizziness, paraesthesia, sexual dysfunction, thrombocytopenia, anaemia, leucopenia, eosinophilia, bone-marrow suppression, myalgia, myopathy, myasthenia, myositis accompanied by increase in creatine kinase, blurred vision, exfoliative dermatitis, alopecia, and photosensitivity
|-
|
|
|Ezetimibe
|Primary and familial hyper-cholesterolaemia
|10mg once daily
|ESC and EAS Guidelines (European Heart Journal (2011) 32, 1769–1818
doi:10.1093/eurheartj/ehr158)
doi:10.1093/eurheartj/ehr158)
Transplant patients (with high LDL-C): Class IIbC gastro-intestinal disturbance including diarrhoea (4.1%) and abdominal pain (3.0%); headache, fatigue (2.4%); myalgia, arthralgia (3.0%), sinusitis (3.6%), pharyngitis (2.3%), viral infection (2.2%), coughing (2.3%), hypersensitivity reactions including rash, angioedema, and anaphylaxis, hepatitis,pancreatitis, cholelithiasis, cholecystitis, thrombocytopenia, raised creatine kinase, myopathy, and rhabdomyolysis
Transplant patients (with high LDL-C): Class IIbC
|Gastro-intestinal disturbance including diarrhoea (4.1%) and abdominal pain (3.0%); headache, fatigue (2.4%); myalgia, arthralgia (3.0%), sinusitis (3.6%), pharyngitis (2.3%), viral infection (2.2%), coughing (2.3%), hypersensitivity reactions including rash, angioedema, and anaphylaxis, hepatitis,pancreatitis, cholelithiasis, cholecystitis, thrombocytopenia, raised creatine kinase, myopathy, and rhabdomyolysis
|
|}
467

edits

Navigation menu